within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L02B_HormoneAntagonistsAndRelatedAgents.L02BX04_Relugolix;

model Relugolix
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.12,
    Cl = 8.166666666666666e-06,
    adminDuration = 600,
    adminMass = 120 / 1000000,
    adminCount = 1,
    Vd = 0.39,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.005333333333333333,
    Tlag = 10.020000000000001,
    Vdp = 2.93,
    k12 = 1.9583333333333336e-05,
    k21 = 1.9583333333333336e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Relugolix</td></tr><tr><td>ATC code:</td><td>L02BX04</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>120</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>390</td><td>L</td></tr>
    <tr><td>clearance:</td><td>29.4</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Relugolix is a non-peptide, orally active gonadotropin-releasing hormone (GnRH) receptor antagonist used to treat advanced prostate cancer and uterine fibroids. It works by reducing the amounts of luteinizing hormone and follicle-stimulating hormone, thereby lowering testosterone or estrogen levels. It is approved for clinical use.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic parameters in adult males with advanced prostate cancer after multiple oral doses. Parameters are based on data from healthy adult volunteers and prostate cancer patients.</p><h4>References</h4><ol><li><p>George, DJ, et al., &amp; Shore, ND (2023). Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer. <i>Clinical genitourinary cancer</i> 21(3) 383–392.e2. DOI:<a href=\"https://doi.org/10.1016/j.clgc.2023.03.009\">10.1016/j.clgc.2023.03.009</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37062659/\">https://pubmed.ncbi.nlm.nih.gov/37062659</a></p></li><li><p>Suzuki, H, et al., &amp; Suzuki, K (2019). Phase I trial of TAK-385 in hormone treatment-naïve Japanese patients with nonmetastatic prostate cancer. <i>Cancer medicine</i> 8(13) 5891–5902. DOI:<a href=\"https://doi.org/10.1002/cam4.2442\">10.1002/cam4.2442</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31429205/\">https://pubmed.ncbi.nlm.nih.gov/31429205</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L02BX04 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Relugolix;
